Anne Schaefer, MD, PhD
- PROFESSOR | Neuroscience
- PROFESSOR | Psychiatry
Research Topics:Basal Ganglia, Brain, Chromatin, Epigenetics, Genetics, Human Genetics and Genetic Disorders, Knockout Mice, Locomotion, Mental Retardation, Multiple Sclerosis
Dr. Anne Schaefer MD, is a Tenured Professor and Vice-Chair in the Department of Neuroscience, Professor in the Department of Psychiatry, and Co-director of the Center for Glial Biology at the Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai. She did her graduate studies at the Johannes Gutenberg University Mainz, the Charité University Berlin and The Rockefeller University in New York. She joined Mount Sinai to start her own laboratory in 2011 after the completion of her postdoctoral studies in Dr. Paul Greengard's Laboratory at The Rockefeller University, New York. Among others, Dr. Schaefer has been awarded with the NIH Director’s New Innovator Award, the Inaugural Landis Mentoring Award for Outstanding Mentorship by the NIH, Cure Challenge Award, and was named a Kavli Frontiers of Science Fellow by the National Academy of Sciences in 2014 and Inventor of the Year 2018 by Mount Sinai.
Click here for more information on Dr. Schaefer's 2012 Director’s New Innovator Award from the National Institutesof Health (NIH).
Visit Anne Schaefer's Laboratory of Brain Epigenetics for more information.
Multi-Disciplinary Training AreaNeuroscience [NEU]
MD, Johannes Gutenberg University
MD, Charité University
Postdoc, The Rockefeller University
Inaugural NINDS Landis Award for Outstanding Mentorship
Inventor of the Year 2018 Award
Harold and Golden Lamport Research Award
Technology Development Fund Award
Cure Challenge Award
Kavli Frontiers in Science Fellow
Chrissy Rossi Investigator
NIH Director’s New Innovator Award
NARSAD Young Investigator Award
Hans-Hench Award 2005
Summa cum lauden
USA Research Scholarship
Our research focuses on identifying the epigenetic basis of neurodegenerative and psychiatric disorders. We study how miRNAs and histone modifying enzymes contribute to the establishment and maintenance of neuronal identity and specialized functions. We are particularly interested in understanding the epigenetic mechanisms of cellular plasticity and its role in regulation of microglia-neuron communication in health and disease. One of the major focuses of our research lies in the development of animal models of human neurological disease associated with abnormal function of epigenetic regulators of different types. Using pioneering technologies including cell type specific analysis of mRNAs, miRNAs and chromatin modifications in neurons in vivo, our research aims at understanding the mechanism of neurological disorders and at their potential treatment by targeting the neuronal epigenome.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Schaefer during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- GlaxoSmithKline; Regenxbio; The Rockefeller University
Scientific Advisory Board:
- Max Planck Institute
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.